July 2017 By Jeremiah Johnson and Richard Jefferys INTRODUCTION Recent advances in the research, development, and implementation of biomedical HIV prevention—primarily in the form of treatment as prevention (TasP) and tenofovir disoproxil fumarate (TDF)/ emtricitabine (FTC) as pre-exposure prophylaxis (PrEP)—already…
July 2017 By Tim Horn INTRODUCTION The antiretroviral (ARV) pipeline remains robust, with several drugs, coformulations, and biologics currently in Phase II and III stages of development. The trends are clear: maximizing the safety and efficacy of standard three-drug regimens;…
Objectives for Module 1: Discuss the difference between HIV prevention for HIV-negative people, HIV prevention for people living with HIV, and HIV testing Discuss the evidence-based HIV prevention options we have available Overview of new tools in development In many…
Objectives for Module 2: Discuss what HEALTH INDICATORS are, what they are not, and why they are important Look at some of the current indicators and relevant research to see how well we’re doing with HIV prevention in key populations…
Objectives for Module 3: Discuss examples of “structural determinants” and “social determinants” of health that drive the HIV epidemic Discuss the difference between individual, structural, and social interventions Look at examples of structural and social interventions for HIV prevention Current…
Objectives for Module 4: Review a brief history of HIV/AIDS policy advocacy Understand basic tactics for policy advocacy and how it differs from other kinds of advocacy Go over suggestions for developing an advocacy agenda and action plan Discuss some…
On May 3, 2017, Treatment Action Group (TAG) and the DARE Collaboratory Community Advisory Board held a community webinar to provide an update on research results presented at the Conference in Retroviruses and Opportunistic Infections (CROI). The webinar was presented by TAG's Basic…
